ERCC6L Polyklonaler Antikörper

• Featured Product
• KD/KO Validated

ERCC6L Polyklonal Antikörper für IHC, WB, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus

Anwendung

WB, IHC, ELISA

Konjugation

Unkonjugiert

Publikationen

7

Kat-Nr. : 15688-1-AP

Synonyme

ERCC6L, PICH, Tumor antigen BJ HCC 15

---

Galerie der Validierungsdaten

• 

  WB analysis of human heart using 15688-1-AP

  human heart tissue were subjected to SDS PAGE followed by western blot with 15688-1-AP (ERCC6L antibody) at dilution of 1:800 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 15688-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 15688-1-AP (ERCC6L antibody) at dilution of 1:3000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of mouse lung using 15688-1-AP

  mouse lung tissue were subjected to SDS PAGE followed by western blot with 15688-1-AP (ERCC6L antibody) at dilution of 1:800 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human colon cancer using 15688-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 15688-1-AP (ERCC6L antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human colon cancer using 15688-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 15688-1-AP (ERCC6L antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: HeLa-Zellen, humanes Herzgewebe, Jurkat-Zellen, K-562-Zellen, Mauslungengewebe, U2OS-Zellen
• Erfolgreiche Detektion in IHC: humanes Kolonkarzinomgewebe; Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen.

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:1000-1:6000
• Immunhistochemie (IHC): IHC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• KD/KO: See 2 publications below
• WB: See 7 publications below
• IHC: See 2 publications below

Produktinformation

15688-1-AP bindet in WB, IHC, ELISA ERCC6L und zeigt Reaktivität mit human, Maus

• Getestete Reaktivität: human, Maus
• In Publikationen genannte Reaktivität: human, Maus
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: ERCC6L fusion protein Ag8223
• Vollständiger Name: excision repair cross-complementing rodent repair deficiency, complementation group 6-like
• Berechnetes Molekulargewicht: 419 aa, 46 kDa, 141 kDa
• Beobachtetes Molekulargewicht: 180 kDa
• GenBank-Zugangsnummer: BC008808
• Gene symbol: ERCC6L
• Gene ID (NCBI): 54821
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3.
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

ERCC6L, also named as Tumor antigen BJ-HCC-15 or PICH, is a 1250 amino acid protein, which contains one helicase ATP-binding domain, one helicase C-terminal domain and two TPR repeats. ERCC6L localizes to kinetochores, inner centromeres and belongs to the SNF2/RAD54 helicase family. ERCC6L as a DNA helicase that acts as an essential component of the spindle assembly checkpoint. The calculated molecular weight of ERCC6L is 140 kDa, but the phosphorylated modification of molecular weight of ERCC6L is about 180kDa.

Publikationen

Species	Application	Title
human	WB	Eur J Med Res; Potential 'anti-cancer' effects of esketamine on proliferation, apoptosis, migration and invasion in esophageal squamous carcinoma cells; Authors - Chao Li
human,mouse	WB	J Ethnopharmacol; Gypenoside LI arrests the cell cycle of breast cancer in G0/G1 phase by down-regulating E2F1.; Authors - Ma-Li Zu
human	WB	Oncol Rep; Overexpression of ERCC6L correlates with poor prognosis and confers malignant phenotypes of lung adenocarcinoma.; Authors - Xiaoyue Huang
human	WB	BMC Cancer; ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway.; Authors - Han Chen ; KD Validated
human	WB,IHC	Oncol Lett; ERCC6L promotes cell growth and invasion in human colorectal cancer.; Authors - Yang Xie ; KD Validated
human	WB,IHC	Cancer Res; PICH activates Cyclin A1 transcription to drive S-phase progression and chemoresistance in gastric cancer; Authors - Huili Ye